We Have the Long-Awaited News About Who Will Control the Minnesota State House
60 Minutes Reporter Who Told Trump Hunter's Laptop Can't Be Verified Afraid Her...
Wait, Is Joe Biden Even Up to Sign the New Government Spending Bill?
Van Jones Has Been on a One-Man War Against the Dems
Van Jones Clears the Air About Donald Trump With a Former CNN Editor,...
Whoopi Goldberg Shares an Insane Theory About Trump, Vance, and Elon Musk
When in Charge, Be in Charge
If You Try to Please Everybody, You’ll End Up Pleasing Nobody
University of Arizona ‘Art’ Exhibit Demands Destruction of Israel
Biden-Harris Steered Us Toward Economic Doom; Trump Will Fix It
Argentina’s Milei Seems to Have Cracked the Code on How to Cut Government...
The Founding Fathers Were Geniuses
KJP Gets Absolutely Grilled By Reporters Over Biden 'Quiet Quitting' His Duties
Republicans Celebrate 'Huge Win' for Trump In Congress After Third Spending Bill Passes
Biden Admin Withdraws Proposed Title IX Sports Rule Change
Tipsheet

Beckman Finally Receives FDA Clearance on Troponin

Danaher Corp. (DHR, $69.77) announced Thursday afternoon that its subsidiary, Beckman Coulter, has received FDA clearance of its new Access AccuTnI+3 troponin I assay for use on the UniCel DxI series of immunoassay systems.Beckman, with expertise in cardiac disease management, was acquired by Danaher in 2011, after problems with its cardiac test,Troponin, led to a recall and financial problems.The FDA approval is a minor positive for Danaher stock, and closes the door on a difficult period in Beckman’s history.

Advertisement

Danaher is a science and technology company that manufactures diversified products, with locations in more than 50 countries. Its revenues are expected to grow 8 and 9% in 2013 and ’14 through internal growth via new and enhanced products, and through acquisitions.

Earnings are expected to grow 7-12% per year over the next three years, from expense control, and margin enhancement via the consolidation of recent acquisitions. The PE is 20.5, in a steady five-year range of 12-23.

The company has a solid balance sheet and strong cash flow, with intentions to repurchase 10 million shares, invest in R&D, and continue acquiring companies.

Danaher’s stock price is on a steady, long-term uptrend and appears immediately capable of continuing to climb.The valuation seems pricey, and I would instead concentrate new purchases on stocks with faster earnings growth.If I were enamored with Danaher and intent on owning shares, I’d wait, and hope for a pullback below $66.

Advertisement

Stock chart:

DHR Chart

DHR data by YCharts

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement